Metabolomics characterization for patients with Rheumatoid Arthritis using spectroscopy
In May, the XXIX Convention of the Spanish Atherosclerosis Society (SEA) took place in Granada, and its scientific committee chose one of the I+D projects developed in Biosfer Teslab to be presented as an oral communication. The presented Communication, whose title is “MEtabolomics characterization for patients with Rheumatoid Arthritis (RA) using 1H-Nuclear magnetic resonance (1H […]
Els especialistes reclamen que la nova prova de determinació de Lipoproteïnes s’utilitzi ja a la pràctica clínica
Biosfer Teslab va asistir al XXIX Congres Nacional de la Societat Espanyola d’Arteriosclerosi (SEA), celebrat a Granada el passat mes de Maig. Concretament, el test Liposcale va ser el tema principal de la Taula Rodona en la qual van participar el Dr. Fernández Pardo, Luis Masana Marín, Domingo Orozco i Núria Amigó Grau. Més informació […]
Especialists ask for the use in clinical practise of the new Lipoprotein determination test
Biosfer Teslab took part in the XXIX National Convention of the Spanish Atherosclerosis Society (SEA), held this past May. Specifically, the Liposcale test was the main topic of the Round Table with the presence of Fernández Pardo, Luis Masana Marín, Domingo Orozco and Núria Amigó Grau. More information here.
Biosfer Teslab in the 8th National Cardiovascular Meeting of SEMERGEN
On the 21th of May, Biosfer Teslab took part in the 8th Cardiovascular Meeting of SEMERGEN, in Santander. Nuria Amigó took part in a session which name was “The significance of the size of lipoproteins in cardiovascular risk filtering. More information here.
The Di@bet.es 2 study will define risk scales that will let us apply prevention programs for less people, but better targeted
The Research Program of CIBERDEM is focused on the study of the epidemiology of diabetes mellitus; genetics, epigenetics and related environmental factors with this pathology, and the associated molecular mechanisms to the onset and progress of the cronical complications of the diabetes. In addition, in the framework of this program, there are other nutritional issues […]
Prize-giving for young talents
Biosfer Teslab was awarded with one of the Premis Gresol for Young talents in front of 250 people at Flash Back room, Salou, from the Gresol Fundation. These prizes reclaim the talent of entrepreneurs and professionals from the regions of Camp de Tarragona and reinforce the values of the business world. More information here.
Biosfer Teslab to Boston
Biosfer to Boston, one of the 20 finalists projects of the international startups acceleration program, The Big Booster More information here.
Biosfer Teslab in the newspaper la Vanguardia
News about Biosfer Teslab appeared in the reportage of the la Vanguardia newspaper, 25 of October, 2015, it’s title was “Un test més efectiu per al ‘colesterol dolent’” that means “A more efective test for the ‘bad cholesterol’” More information here.
Open call to join our operations team
Biosfer Teslab, an in vitro diagnostic company that develops novel NMR-based tests to improve cardiovascular risk assessment in patients at high cardio-metabolic risk, is looking for candidates to join our operations team. The company arises from the research carried out at the Metabolomics Platform and the Lipids and Atherosclerosis Research Unit from the Rovira i […]
Open call for an Industrial Doctorate
Biosfer Teslab, an in vitro diagnostic company that develops novel NMR-based tests to improve cardiovascular risk assessment in patients at high cardio-metabolic risk, is looking for Industrial Doctorate candidates. The company arises from the research carried out at the Metabolomics Platform and the Lipids and Atherosclerosis Research Unit from the Rovira i Virgili University and […]
